Published: Aug, 2018
Transparency Market Research (TMR) observes that the global diabetic neuropathy market is competitive and fairly consolidated due to presence of strong players counting for the larger share. Some of the key players operating in the global diabetic neuropathy market includes Johnson & Johnson, Pfizer, Inc., NeuroMetrix, Inc., Boehringer Ingelheim GmbH, Astellas Pharma Inc., GlaxoSmithKline plc, Eli Lilly and Company, Depomed, Inc., Glenmark Pharmaceuticals Ltd, Lupin Limited, and Arbor Pharmaceuticals, LLC. Leading players are adopting the key strategies such as mergers, acquisitions, and partnerships which improved their product portfolio and helped them to expand their reach. Additionally, global players are increasingly investing their money on research and development (R&D) activities for introduction of new products.
The global revenue of the diabetic neuropathy market was registered at US$3.6 bn in 2016 and expected to expand with a CAGR of 5.4% to attain the value of US$ 5.718 bn by the year 2024. On the basis of region, North America accounted for the leading share of revenue of around 34.9% of the overall market. This growth is attributable to presence of a large pool of diabetic patients and expensiveness of other therapies. North America was valued at US$ 1.071 bn in year 2016 and it is expected to expand with a growth rate of 5.3% CAGR over the forecast period from 2017 to 2025 to attain the value of US$ 1.68 bn by the end of 2025. Among the disorders type, proximal neuropathy is expected to witness growth with the highest CAGR of 5.7% over the forecast period.
Need of Treatments on Diabetic Neuropathic to Boost Growth
Diabetes is one of the metabolic disorder and most common problem found in nearly 30.3 mn people alone in the US which is nearly 9.4% of the US population. Among these amount of patients, about 60 to 70% of patients of diabetes have some issues in form of neuropathy. The diabetic neuropathies are some of the nerve disorders mainly caused by diabetes which can damage the nerves throughout the body. Prevention of diabetic neuropathies includes glucose control and lifestyle modification. Rising prevalence of the diseases are boosting need of the treatments on diabetic neuropathic which is likely to drive growth of the global diabetic neuropathy market.
In addition, the factors like sedentary lifestyle and urbanization have led to change in the eating habits, and genetic composition is resulting in to increasing prevalence of obesity and numerous cardiovascular diseases. In order to reduce these occurrence numerous health organizations and governments are taking initiatives which is expected to boost growth of the global diabetic neuropathy market. For instance, National Institute of Neurological Disorders and Stroke (NINDS) are increasingly providing funds in research activities on neuropathy. Additionally, several Non-governmental organizations (NGOs) operating in the developing countries are taking some steps to control diabetes and withdraw symptoms of diabetic neuropathy. These initiatives are driving growth of the global diabetic neuropathy market.
High Cost of Treatment to Hamper Growth
However, high cost of the treatment of neuropathy is expected to restrain growth of the global diabetic neuropathy market. Nevertheless, the growing number of healthcare awareness programs, and increasing investments in improving healthcare facilities mainly improving hospitals equipped with radiology devices to treat diabetic neuropathy, and a large pool of patients in the emerging countries such as India and China are creating lucrative opportunities to players in the global diabetic neuropathy market.
This information is comprised in the new report by TMR, titled “Diabetic Neuropathy Market (Disorder Type - Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy; Treatment Type - Drugs (Analgesic (Topical, Opioid, and NSAIDs), Antidepressants (TCAs, SNRIs, and SSRIs), and Anticonvulsant Drugs (Gabapentin, Pregabalin, and Topiramate), Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS)), and Physiotherapy; Distribution Channel - Hospitals, Clinics, Retail Pharmacy, and Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.”
The global diabetic neuropathy market has been segmented as presented:
By Disorder Type:
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
By Treatment Type:
- Anticonvulsant Drugs
- Transcutaneous Electrical Nerve Stimulation (TENS)),
By Distribution Channel:
- Retail Pharmacy
- Online Pharmacy
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453